Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cannabinoids vs other anti‐emetic agent Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 1.1 [0.86, 1.4] | 4 studies · 209 participants | Moderate |
Cannabinoids vs other anti‐emetic agent Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy (2015) · Cochrane | RR 2 [0.74, 5.4] | 4 studies · 414 participants | Low |
Benefits and harms of CSF plus antibiotics vs antibiotics alone Overall mortality · people with chemotherapy‐induced febrile neutropenia Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia (2014) · Cochrane | HR 0.74 [0.47, 1.16] | 13 studies · 1335 participants | Low |
Benefits and harms of CSF plus antibiotics vs antibiotics alone Infection‐related mortality · people with chemotherapy‐induced febrile neutropenia Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia (2014) · Cochrane | RR 0.75 [0.47, 1.2] | 10 studies · 897 participants | Low |
Benefits and harms of CSF plus antibiotics vs antibiotics alone People hospitalized for > 10 days · people with chemotherapy‐induced febrile neutropenia Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia (2014) · Cochrane | RR 0.65 [0.44, 0.95] | 7 studies · 1087 participants | Low |
Benefits and harms of CSF plus antibiotics vs antibiotics alone Duration of grade IV neutropenia (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia (2014) · Cochrane | no estimate extracted | 9 studies · 1135 participants | Low |
Benefits and harms of CSF plus antibiotics vs antibiotics alone Time to recovery from fever (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia (2014) · Cochrane | no estimate extracted | 9 studies · 966 participants | Low |
Benefits and harms of CSF plus antibiotics vs antibiotics alone Time to withdrawal from ATB (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia (2014) · Cochrane | no estimate extracted | 3 studies · 457 participants | Low |
Benefits and harms of CSF plus antibiotics vs antibiotics alone Deep vein thrombosis · people with chemotherapy‐induced febrile neutropenia Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia (2014) · Cochrane | RR 1.68 [0.72, 3.93] | 4 studies · 389 participants | Low |
TMP/SMX vs placebo, no treatment or non‐PCP drug Documented PCP infections Clinical and microbiological criteria · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients (2014) · Cochrane | no estimate extracted | 10 studies · 1000 participants | Moderate |
TMP/SMX vs placebo, no treatment or non‐PCP drug All cause mortality ‐ TMP/SMX versus placebo or no treatment · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients (2014) · Cochrane | RR 0.58 [0.17, 2] | 4 studies · 461 participants | Low |
TMP/SMX vs placebo, no treatment or non‐PCP drug PCP‐related mortality Clinical only · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients (2014) · Cochrane | RR 0.17 [0.03, 0.94] | 9 studies · 886 participants | Low |
TMP/SMX vs placebo, no treatment or non‐PCP drug Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients (2014) · Cochrane | RR 0.28 [0.05, 1.7] | 5 studies · 530 participants | Moderate |
Intervention NR 3‐year overall survival rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 0.95 [0.79, 1.15] | 1 study · 206 participants | Low |
Intervention NR Locaregional recurrence · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 1.09 [0.83, 1.43] | 4 studies · 976 participants | Moderate |
Intervention NR Distant metastasis · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 0.99 [0.72, 1.35] | 4 studies · 976 participants | Moderate |
Intervention NR 5‐year overall survival rate (3 to 6 yr) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 0.93 [0.84, 1.04] | 2 studies · 912 participants | Low |
Intervention NR 10‐year overall survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 0.79 [0.52, 1.2] | 1 study · 430 participants | Moderate |
Intervention NR 5‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 0.95 [0.84, 1.07] | 2 studies · 562 participants | Moderate |
Intervention NR 10‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 1.02 [0.88, 1.19] | 1 study · 430 participants | Moderate |
Intervention NR 3‐year relapse‐free survive rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 1.04 [0.71, 1.52] | 1 study · 206 participants | Low |
Intervention NR 5‐year relapse‐free survive rate (66 mo) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 0.96 [0.81, 1.14] | 1 study · 132 participants | Low |
Intervention NR 3‐year local control rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 0.95 [0.86, 1.05] | 1 study · 206 participants | Low |
Intervention NR 5‐year local control rate (3 to 6 yr) · women with locally advanced uterine cervix cancer High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer (2014) · Cochrane | RR 0.95 [0.87, 1.05] | 1 study · 482 participants | Low |
Intervention NR Recurrence rate at 1 year · women with high‐grade VIN Surgical interventions for high‐grade vulval intraepithelial neoplasia (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall Survival (median · Patients with brain metastases Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain… (2014) · Cochrane | HR 1.11 [0.83, 1.48] | 5 studies · 663 participants | Low |
Intervention NR Progression free survival · Patients with brain metastases Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain… (2014) · Cochrane | HR 0.76 [0.53, 1.1] | 2 studies · 378 participants | Low |
Intervention NR Any intracranial disease progression at 1 year · Patients with brain metastases Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain… (2014) · Cochrane | RR 0.46 [0.35, 0.6] | 4 studies · 304 participants | Low |
Intervention NR Neurocognitive function · Patients with brain metastases Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain… (2014) · Cochrane | no estimate extracted | 3 studies · 209 participants | Low |
Intervention NR Health related quality of life · Patients with brain metastases Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain… (2014) · Cochrane | no estimate extracted | 3 studies · 436 participants | Low |
Intervention NR Adverse events · Patients with brain metastases Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain… (2014) · Cochrane | no estimate extracted | 4 studies · 568 participants | Low |
Image guided surgery vs standard surgery Complete resection ‐ iMRI · high grade glioma Image guided surgery for the resection of brain tumours (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR 5‐ year OS · women with stage III or IV endometrial cancer after primary cytoreductive surgery Adjuvant chemotherapy for advanced endometrial cancer (2014) · Cochrane | HR 0.75 [0.57, 0.99] | 2 studies · 620 participants | Moderate |
Intervention NR 5‐year PFS · women with stage III or IV endometrial cancer after primary cytoreductive surgery Adjuvant chemotherapy for advanced endometrial cancer (2014) · Cochrane | HR 0.74 [0.59, 0.92] | 2 studies · 620 participants | Moderate |
Intervention NR 5‐year OS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery Adjuvant chemotherapy for advanced endometrial cancer (2014) · Cochrane | HR 0.76 [0.57, 1.02] | 2 studies · 514 participants | Moderate |
Intervention NR 5‐year PFS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery Adjuvant chemotherapy for advanced endometrial cancer (2014) · Cochrane | HR 0.81 [0.63, 1.05] | 2 studies · 514 participants | Moderate |
Intervention NR PFS (stage III/IV) Median · women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy Adjuvant chemotherapy for advanced endometrial cancer (2014) · Cochrane | HR 0.9 [0.69, 1.17] | 1 study · 552 participants | Moderate |
beta‐lactam monotherapy vs beta‐lactam‐aminoglycoside combination therapy All cause mortality · febrile neutropenic cancer patients. Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia (2013) · Cochrane | RR 0.87 [0.75, 1.02] | 44 studies · 7186 participants | High |
beta‐lactam monotherapy vs beta‐lactam‐aminoglycoside combination therapy Any nephrotoxicity ‐ Ag dosing regimen (Copy) · febrile neutropenic cancer patients. Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia (2013) · Cochrane | RR 0.45 [0.35, 0.57] | 39 studies · 6608 participants | High |
beta‐lactam monotherapy vs beta‐lactam‐aminoglycoside combination therapy Treatment failure ‐ same beta‐lactam · febrile neutropenic cancer patients. Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia (2013) · Cochrane | RR 1.11 [1.02, 1.2] | 16 studies · 2833 participants | Moderate |
beta‐lactam monotherapy vs beta‐lactam‐aminoglycoside combination therapy Treatment failure ‐ different beta‐lactam · febrile neutropenic cancer patients. Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia (2013) · Cochrane | RR 0.92 [0.88, 0.97] | 55 studies · 7736 participants | Low |
Oral vs intravenous antibiotic therapy Mortality · patients with febrile neutropenia in cancer patients Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients (2013) · Cochrane | RR 0.95 [0.54, 1.68] | 9 studies · 1392 participants | Moderate |
Oral vs intravenous antibiotic therapy Treatment failure · patients with febrile neutropenia in cancer patients Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients (2013) · Cochrane | RR 0.96 [0.86, 1.06] | 22 studies · 3142 participants | Moderate |
Oral vs intravenous antibiotic therapy Treatment failure ‐ per protocol analysis · patients with febrile neutropenia in cancer patients Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients (2013) · Cochrane | RR 0.98 [0.86, 1.11] | 22 studies · 2912 participants | Moderate |
Oral vs intravenous antibiotic therapy Adverse events requiring discontinuation of antibiotics · patients with febrile neutropenia in cancer patients Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients (2013) · Cochrane | RR 1.45 [0.61, 3.46] | 15 studies · 1823 participants | Low |
Oral vs intravenous antibiotic therapy Treatment failure not dt modification in update · patients with febrile neutropenia in cancer patients Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients (2013) · Cochrane | RR 0.95 [0.85, 1.06] | 21 studies · 3041 participants | Moderate |
Maintenance chemotherapy vs observation 3‐year PFS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane | RR 1.07 [0.91, 1.25] | 4 studies · 541 participants | Moderate |
Platin‐based maintenance chemotherapy vs observation 3‐year OS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane | RR 1.06 [0.94, 1.18] | 3 studies · 341 participants | Moderate |
Platin‐based maintenance chemotherapy vs observation 5‐year OS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane | RR 1.07 [0.88, 1.31] | 2 studies · 219 participants | Moderate |
Platin‐based maintenance chemotherapy vs observation 10‐year OS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane | RR 1.08 [0.78, 1.49] | 2 studies · 219 participants | Moderate |